Base de dados : LILACS
Pesquisa : D03.383.663.283.266.450.268.777 [Categoria DeCS]
Referências encontradas : 22 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 22 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-886210
Autor: Özer, Nazmi; Bülbüloğlu, Ertan; Yormaz, Serdar; Ece, İlhan.
Título: Evaluation of silybum marinaum efficacy on University of Wisconsin and histidine-tryptophan-ketoglutarate solutions latter the damage of the perfused liver
Fonte: Acta cir. bras;32(6):407-417, June 2017. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To investigate the hepatoprotective and antioxidant effeicacies of Silybum marianum's (silymarin, S) on University of Wisconsin (UW) and histidinetryptophan-ketoglutarate (HTK) preservation solutions. Methods: Thirty two Wistar albino adult male rats were used. Group 1: UW group, Group 2: UW + Silymarin group(S), Group 3: HTK group, Group 4: HTK + silymarin group (S), respectively. Silymarin was enforced intraperitoneally before the surgery. Biopsies were enforced in 0, 6 and 12.hours to investigate. Results: Biochemical parameters examined in alanine aminotransferase (ALT), furthermore superoxide dismutase (SOD), catalase (CAT), and malondialdehyde (MDA) in rats were also evaluated. Detected histopathological changings were substantially declining in the groups that received silymarin, cellular damage was decreased significantly in HTK + Silymarin group, according to other groups. It has been identified as the most effective group was HTK + silymarin group in evaluation of ALT, electron microscopic results, also decreased MDA and elevated in SOD, and CAT activity. Caspase 3 analysis showed a substantial lower apoptosis ratio in the silymarin groups than in the non-performed groups (p<0.05). Conclusion: Histidinetryptophan-ketoglutarate+silymarin group provides better hepatoprotection than other groups, by decreasing the hepatic pathologic damage, delayed changes that arise under cold ischemic terms.
Descritores: Silimarina/uso terapêutico
Soluções para Preservação de Órgãos
Substâncias Protetoras/uso terapêutico
Doença Hepática Induzida por Substâncias e Drogas/tratamento farmacológico
Antioxidantes/uso terapêutico
-Cloreto de Potássio
Procaína
Rafinose
Imuno-Histoquímica
Adenosina
Alopurinol
Ratos Wistar
Modelos Animais de Doenças
Glucose
Glutationa
Insulina
Manitol
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  2 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-837659
Autor: Onalan, Ali Kemal; Tuncal, Salih; Kilicoglu, Sibel; Celepli, Salih; Durak, Esra; Kilicoglu, Bulent; Devrim, Erdinc; Barlas, Aziz Mutlu; Kismet, Kemal.
Título: Effect of silymarin on oxidative stress and liver histopathology in experimental obstructive jaundice model
Fonte: Acta cir. bras;31(12):801-806, Dec. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT PURPOSE: To investigate the effect of silymarin on oxidative stress and hepatic injury induced by obstructive jaundice in an experimental model. METHODS: Thirty Wistar-Albino type female rats were divided into 3 groups each including 10 rats. Only laparotomy was performed in group 1. Bile duct ligation was performed in group 2. In group 3, bile duct ligation was performed and orogastic silymarin 300 mg/kg/day dose was given for seven days. At the end of seven days, rats were sacrificed. The blood and liver tissue samples were taken to be examined biochemically and histopathologically. RESULTS: The plasma and liver levels of malondialdehyde were significantly lower in silymarin group than in the bile duct ligated group. Although liver levels of GSH were significantly higher in silymarin group than in the bile duct ligated group, there was no significant difference between the plasma GSH levels of these groups. In silymarin group; the enlargement of hepatocytes, dilatation of canaliculi and the edema were regressed. CONCLUSION: Silymarin diminished the harmful effects of obstructive jaundice on liver.
Descritores: Silimarina/farmacologia
Estresse Oxidativo/efeitos dos fármacos
Icterícia Obstrutiva/complicações
Fígado/patologia
Antioxidantes/farmacologia
-Ductos Biliares
Distribuição Aleatória
Ratos Wistar
Substâncias Protetoras/farmacologia
Icterícia Obstrutiva/patologia
Glutationa/sangue
Ligadura
Malondialdeído/sangue
Limites: Animais
Feminino
Ratos
Responsável: BR1.1 - BIREME


  3 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-781326
Autor: Ergün, Yusuf; Üremiş, Muhammed; Kılınç, Metin; Alıcı, Tuğrul.
Título: Antioxidant effect of Legalon(r) SIL in ischemia-reperfusion injury of rat skeletal muscle
Fonte: Acta cir. bras;31(4):264-270, Apr. 2016. tab, graf.
Idioma: en.
Resumo: PURPOSE: To evaluated the potential antioxidant agent Legalon (r) SIL (silibinin-C-2',3-bis(hydrogensuccinat)) in the skeletal muscle of rats. METHODS: IRI was achieved via tourniquet application in Wistar-albino rats. Experimental groups were chosen as (i) sham control, (ii) IRI (3+2 h), (iii) IRI and Legalon (r) SIL-50 (50 mg/kg/i.p.), (iv) IRI and Legalon (r) SIL-100 (100 mg/kg/i.p.), and (v) IRI and Legalon (r) SIL-200 (200 mg/kg/ i.p.). Muscle viability (evaluated by triphenyltetrazolium chloride dye method), malondialdehyde, superoxide dismutase, catalase, and glutathione peroxidase were assessed in muscle samples using a spectrophotometer. RESULTS: Although viability of the injured limb non-significantly declined in the IRI group, administration of Legalon (r) SIL did not prevent injury. However, dramatic increase observed in malondialdehyde levels in the IRI group was prohibited by Legalon (r) SIL in a statistically significant manner. In comparison with the sham-control group, IRI and Legalon (r) SIL administration did not cause any significant alterations in the levels of superoxide dismutase, catalase, and glutathione peroxidase. CONCLUSION: Although Legalon (r) SIL was not sufficient to prevent muscle injury in terms of viability, it is found to be an effective option to reduce reactive oxygen species-induced cell injury.
Descritores: Silimarina/farmacologia
Traumatismo por Reperfusão/prevenção & controle
Músculo Esquelético/irrigação sanguínea
Isquemia/prevenção & controle
Antioxidantes/farmacologia
-Valores de Referência
Superóxido Dismutase/análise
Superóxido Dismutase/efeitos dos fármacos
Sobrevivência de Tecidos/efeitos dos fármacos
Catalase/análise
Catalase/efeitos dos fármacos
Distribuição Aleatória
Reprodutibilidade dos Testes
Espécies Reativas de Oxigênio/análise
Ratos Wistar
Estresse Oxidativo/efeitos dos fármacos
Músculo Esquelético/efeitos dos fármacos
Músculo Esquelético/química
Glutationa Peroxidase/análise
Glutationa Peroxidase/efeitos dos fármacos
Malondialdeído/análise
Limites: Animais
Masculino
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  4 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-623946
Autor: Rui, Yao-Cheng.
Título: Advances in pharmacological studies of silymarin
Fonte: Mem. Inst. Oswaldo Cruz;86(supl.2):79-85, 1991. ilus, tab, graf.
Idioma: en.
Conferência: Apresentado em: Brazilian-Sino Symposium on Chemistry and Pharmacology of Natural Products, Rio de Janeiro, Dec. 10-14, 1989.
Resumo: Silymarin is the flavonoids extracted from the seeds of Silybum marianum (L) Gearth as a mixture of three structural isomers: silybin, silydianin and silychristin, the former being the most active component. Silymarin protects liver cell membrane against hepatotoxic agents and improves liver function in experimental animals and humans. It is generally accepted that silymarin exerts a membrane-stabilizing action preventing or inhibiting membrane peroxidation. The experiments with soybean lipoxygenase showed that the three components of silymarin brought about a concentration-dependent non-competitive inhibition of the lipoxygenase. The experiments also showed an analogous interaction with animal lipoxygenase, thus showing that an inhibition of the peroxidation of the fatty acid in vivo was self-evident. Silybin almost completely suppressed the formation of PG at the highest concentration (0.3 mM) and proved to be an inhibitor of PG synthesis in vitro. In our experiments, silybin at lower dose (65 mg/Kg) decreased liver lipoperoxide content and microsomal lipoperoxidation to 84.5% and 68.55% of those of the scalded control rats respectively, and prevented the decrease of liver microsomal cytochrome p-450 content and p-nitroanisole-0-demethylase activity 24 h post-scalding. Effects of silymarin on cardiovascular systen have been studied in this university since 1980. O. O silymarin 800 mg/Kg/d or silybin 600 mg/Kg/d reduced plasma total cholesterol, LDL-C and VLDL-C. They however, enhanced HDL-C in hyperlipenic rats. Further studies showed that silymarin enhanced HDL-C in hyperlipemic rats. Further studies showed that silymarin enhanced HDL-C but didn't affect HDL-C, a property of this component which is beneficial to treatment of atherosclerosis. The results showed silymarin 80 mg or silybin 60 mg decreased in vitro platelet aggregation (porcentagem) in rats. The maximal platelet aggregation induced by ADP declined significantly, and time to reach maximal platelet aggregation and five-minute disaggregation didn't change. In our experiments, iv silybin 22,4 mg/kg lowered the amplitude and duration of diastolic blood pressure (DBP) more than those of systolic (SBP), but the descending aortic blood flow, cardiac contractility and ECG did not change significantly in anesthetized open-chest cats. The results indicated a reduction of peripheral resistance and dilatatory action on the resistant blood vessels. These effects are beneficial to coronary heart disease. We also observed the effects of silybin on morphological change, the release of glutamic oxaloacetate aminotrasferase (GOT) and lactate dehydrogenase (LDH) as well as the radioactivity of 3H-TdR incorporated into DNA in normal cardiac cells and cells infected by coxsackie B5, virus os newborn rats. The results showed that silynin did not affect the morphology of normal cell, and that the pathological change of cells infected by virus was delayed and reduced as compared to control. We have investigated the effect of silybin on synthesis and release of LTs in the cultured porcine cerebral basilar arteries (PCBA). Silybin 100 and 500 µmol/L declined the amounts of LTs released from the PCBA incubsated in the presence of A 23187, AA and indomenthacin. The result suggests that silybin can inhibit the activity of 5-lipoxygenase of cerebral blood vessel and may protect the brain from ischemia.
Descritores: Silimarina/uso terapêutico
Inibidores da Agregação de Plaquetas/farmacologia
Sistema Cardiovascular/efeitos dos fármacos
Inibidores de Lipoxigenase/farmacologia
Hemodinâmica/efeitos dos fármacos
Antioxidantes/farmacologia
-Lipídeos/sangue
Fígado
Limites: Animais
Responsável: BR1.1 - BIREME


  5 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-974416
Autor: Vaezi, Maryam; Yaghmaei, Parichehreh; Hayati-Roodbari, Nasim; Irani, Shiva; Ebrahim-Habibi, Azadeh.
Título: Citral effect in male NMRI mice nonalcoholic steatosis model: assessing biochemical and histological parameters and PPARα gene expression
Fonte: Braz. J. Pharm. Sci. (Online);54(3):e17596, 2018. tab, graf.
Idioma: en.
Resumo: Citral is a small molecule present in various citrus species, with reported anti-hyperlipidemic and anti-inflammation effects. Here, the effect of intraperitoneal (IP) administration of citral is evaluated in a mouse model of non-alcoholic steatosis. Male NMRI mice were divided into the following groups (n = 12): normal control group (NC) receiving a normal diet; high-fat emulsion group (HF) receiving high fat diet for four weeks; positive control group (C+) receiving HF diet for four weeks and then shifted to normal diet with IP-administered silymarin (80 mg/kg) for four weeks; sham group receiving HF diet for four weeks and then shifted to normal diet for four weeks; and EC1, EC2, and EC3 groups receiving HF diet for four weeks and then shifted to normal diet with IP-administered citral doses of 5, 10, and 20 mg/kg, respectively. HF diet resulted in steatohepatitis with impaired lipid profile, high glucose levels and insulin resistance, impaired liver enzymes, antioxidants, adiponectin and leptin levels, decreased PPARα level, and fibrosis in the liver tissue. Upon treatment with citral, improvement in condition was observed in a dose-dependent manner-both at histological level and in the serum of treated animals. and the PPARα level was also increased.
Descritores: Expressão Gênica/fisiologia
PPAR gama/análise
Doença Hepática Terminal/diagnóstico
-Silimarina/farmacologia
Citrus
Hepatopatia Gordurosa não Alcoólica/diagnóstico
Limites: Animais
Masculino
Ratos
Responsável: BR1.1 - BIREME


  6 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-951902
Autor: Yaman, Turan; Uyar, Ahmet; Kaya, Mehmet Salih; Keles, Ömer Faruk; Uslu, Baris Atalay; Yener, Zabit.
Título: Protective effects of silymarin on methotrexate-induced damages in rat testes
Fonte: Braz. J. Pharm. Sci. (Online);54(1):e17529, 2018. tab, graf.
Idioma: en.
Resumo: Abstract The present study aimed to investigate the protective effects of silymarin (SMN), an antioxidant, on methotrexate (MTX)-induced damage in rat testes. Thirty-two Wistar albino rats were divided into four groups (n = 8): control, MTX (20 mg/kg, i.p. on days 1 and 5), SMN (200 mg/kg, orally), and MTX + SMN (20 mg/kg, i.p. on days 1 and 5 and SMN 200 mg/kg orally) groups. At the end of the 6-week trial period, histopathological, immunohistochemical, biochemical, and spermatological analyses were performed on testes tissues. Histopathologically, MTX-induced damage, including depletion of germ cell and loos of spermatozoa, was significantly improved with SMN treatment. Immunohistochemically, the immunoreactivity of glutathione peroxidase 1 (GPx1) and manganese superoxide dismutase 2 (SOD2) were detected more intensely in the MTX + SMN group than in the MTX group. Biochemical examinations revealed that SMN supplementation decreased the lipid peroxidation and increased enzymatic antioxidants in the SMN-treated rats. Spermatologically, significant differences were found in the density, motility, dead-to-live sperm ratio, and abnormal sperm rate in the MTX + SMN group compared to the MTX group. In conclusion, SMN seems to have protective effects as an antioxidant against MTX-induced damage in rat testes.
Descritores: Silimarina/efeitos adversos
Testículo/anormalidades
Substâncias Protetoras/análise
-Metotrexato/análise
Limites: Animais
Masculino
Ratos
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  7 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-954169
Autor: Emam, Mahmoud Abdelghaffar; Farouk, Sameh Mohamed; Abdo, Mohamed.
Título: The ameliorative potential of probiotics and/or silymarin on thioacetamide induced hepatotoxicity in rats: histological and immunohistochemical study / El potencial de mejora de los probióticos y / o silimarina sobre la hepatotoxicidad inducida por tioacetamida en ratas: estudio histológico e inmunohistoquímico
Fonte: Int. j. morphol;36(2):661-669, jun. 2018. graf.
Idioma: en.
Resumo: Thioacetamide (TAA) is one of the common fungicidal agents that induce liver injury varying from inflammation, necrosis, and fibrosis to cirrhosis. Many recent studies reported the beneficial effect of probiotics and silymarin on hepatotoxicity regardless the causative agents. Therefore, the present study aimed to evaluate the ameliorative role of probiotics and/or silymarin on TAA induced hepatotoxicity in rats via histological, and immunohistochemical methods. Twenty five male albino rats were used for this experiment and were divided into five groups (n=5 rats/group); group I acts as negative control, group II was orally administrated distilled water for six weeks, then injected with TAA (200 mg/kg b.wt./ 5 ml physiological saline/ I.P.) twice a week for another six weeks, group III was treated with probiotics at a dose of 135 mg/ kg b.wt. orally in drinking water daily for six weeks, then injected with TAA (dosage of group II), twice weekly for another six weeks, group IV was treated with silymarin at a dose of 200 mg/ kg b.wt orally 4 times per week for six weeks, then injected with TAA (dosage of group II), twice weekly for another six weeks and group V was treated with combination of both probiotics and silymarin, at the same dosage in groups III and IV respectively then injected with TAA (dosage of group II), twice weekly for another six weeks. Histologically, TAA induced hepatocytes degeneration, inflammatory cells infiltration, and pseudolobular parenchyma as well as, high apoptosis and low proliferation rates that were proved by immunohistochemical staining for caspase 3 and ki-67 respectively. Probiotics and/or silymarin improved the histological feature of hepatocytes, reduced apoptosis and stimulated proliferation. Based on these results, we concluded that the use of probiotics and silymarin combination ameliorates the hepatotoxic effect of TAA in rats more than the use of probiotics or silymarin alone.

La tioacetamida (TAA) es uno de los agentes fungicidas más comunes que inducen lesiones hepáticas que varían desde inflamación, necrosis y fibrosis hasta cirrosis. Muchos estudios recientes informaron el efecto beneficioso de los probióticos y la silimarina sobre la hepatotoxicidad independientemente de los agentes causantes. Por lo tanto, el presente estudio tuvo como objetivo evaluar el papel paliativo de los probióticos y / o silimarina en la hepatotoxicidad inducida por TAA en ratas a través de métodos histológicos e inmunohistoquímicos. Para este experimento se usaron veinticinco ratas albinas y se dividieron en cinco grupos (n = 5 ratas / grupo); el grupo I se usó como control negativo; en el grupo II se administró por vía oral agua destilada durante seis semanas y luego se inyectó TAA (200 mg / kg b.wt./ 5 ml solución salina fisiológica / IP) dos veces por semana durante otras seis semanas; el grupo III se trató con probióticos, dosis diaria de 135 mg / kg b.wt. por vía oral en agua potable, durante seis semanas y luego fue inyectado con TAA (dosis del grupo II), dos veces por semana durante otras seis semanas; el grupo IV se trató con silimarina, con una dosis de 200 mg / kg b.wt por vía oral 4 veces por semana durante seis semanas, luego se inyectó TAA (dosificación del grupo II), dos veces por semana durante otras seis semanas; y el grupo V, se trató con una combinación de ambos probióticos y silimarina con la misma dosis que en los grupos III y IV, respectivamente, luego fueron inyectados con TAA (dosificación del grupo II), dos veces por semana durante otras seis semanas. Histológicamente, la TAA indujo la degeneración de los hepatocitos, la infiltración de células inflamatorias y el parénquima pseudolobular, así como también una apoptosis alta y tasas de proliferación bajas que se probaron mediante tinción inmunohistoquímica para caspasa 3 y ki-67, respectivamente. Los probióticos y / o la silimarina mejoraron la característica histológica de los hepatocitos, redujeron la apoptosis y estimularon la proliferación. En base a estos resultados, concluimos que el uso de la combinación de probióticos y silimarina mejora el efecto hepatotóxico del TAA en ratas más que el uso de probióticos o silimarina individualmente.
Descritores: Silimarina/administração & dosagem
Tioacetamida/toxicidade
Probióticos/administração & dosagem
Doença Hepática Induzida por Substâncias e Drogas/tratamento farmacológico
-Imuno-Histoquímica
Doença Hepática Induzida por Substâncias e Drogas/patologia
Fígado/efeitos dos fármacos
Limites: Animais
Masculino
Ratos
Responsável: CL1.1 - Biblioteca Central


  8 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-915966
Autor: Gutierrez Machaca, Rosmery; Jimenez Rojas, Janett Jessica.
Título: Efecto protector del extracto acuoso de Peumus boldus (boldo) frente a la inducción de cirrosis hepática con paracetamol y fenobarbital en ratas, comparado con la silimarina, Arequipa 2015 / Protective effect of the aqueous extract of Peumus boldus (boldo) against the induction of hepatic cirrhosis with paracetamol and phenobarbital in rats, compared with silymarin, Arequipa 2015.
Fonte: Arequipa; s.n; 2015. 86 p. tab, graf.
Idioma: es.
Tese: Apresentada a Universidad Mayor de San Agustín de Arequipa para obtenção do grau de Especialista.
Resumo: El objetivo del presente estudio fue determinar el efecto protector del extracto acuoso de Peumus boldus (boldo) frente a la inducción de cirrosis hepática con paracetamol y fenobarbital en ratas comparado con la silimarina. Se realizó un estudio experimental, para el cual se utilizó 20 ratas machos Rattus norvegicus de tres meses de edad, las cuales fueron distribuidas en cuatro grupos de 5 ratas cada uno: control negativo, recibieron agua destilada (1ml/kg de peso) y suero fisiológico (1ml/kg de peso); control positivo, recibieron a diario Agua destilada (1 mllkg de peso); experimental protector, recibieron a diario el extracto acuoso de las hojas de Peumus boldus (boldo) (160mg/Kg de peso); patrón, recibieron a diario la Silimarina (25mg/kg de peso), A los 3 últimos grupos, después de 30 minutos se les administró la dosis tóxica de fenobarbital (0.5mg/ml) el primer día y paracetamol (250mg/Kg de peso) los días 5, 1 O y 15 ambos fármacos vía intraperitoneal. Se tomó pruebas del perfil hepático los días 1, 5, 10 y 15 en sangre, y se estudió la anatomopatología de los hígados. Al finalizar los procedimientos experimentales se encontró que, el control positivo tuvo elevación de transaminasas TGO (119 ± 8,6), TGP (61 ± 8,1), bilirrubina total (1 ,49 ± O, 15), y fosfatasa alcalina (168 ± 35,2); disminución de albúminas (3,1 ± 0,21) y proteínas totales (5,1 ± 0,3); mientras que el grupo protector (boldo), tuvo una disminución significativa de transaminasas TGO (73 ± 9,7), TGP (31 ± 5,4), bilirrubina total (1 ,23 ±O, 13) y fosfatasa alcalina (121 ± 19,5), y un aumento significativo de albúmina (3.82 ± 0,40). El extracto acuoso de Pe u mus boldus (boldo) a una dosis de 160 mg/kg de peso, tiene efecto hepatoprotector frente a la injuria producida por el fenobarbital y paracetamol según parámetros bioquímicos y anatomopatológ icos.
Descritores: Fenobarbital
Ratos
Silimarina
Peumus
Cirrose Hepática Experimental
Acetaminofen
-Peru
Plantas Medicinais
Limites: Animais
Ratos
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  9 / 22 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: biblio-893046
Autor: Kayedpoor, Parvin; Mohamadi, Shima; Karimzadeh-Bardei, Latifeh; Nabiuni, Mohammad.
Título: Anti-inflammatory effect of silymarin on ovarian immunohistochemical localization of TNF-alpha associated with systemic inflammation in polycystic ovarian syndrome / Efecto antiinflamatorio de la silimarina en la localización inmunohistoquímica ovárica del TNF-alfa asociado con la inflamación sistémica en el síndrome de ovario poliquístico
Fonte: Int. j. morphol;35(2):723-732, June 2017. ilus.
Idioma: en.
Resumo: Tumor necrosis factor alpha (TNF-a) and interleukin (IL)-6, are prominent mediators of inflammation and have been confirmed to be elevated in at least a subgroup of women with polycystic ovary syndrome (PCOS). In this study, the effects of Silymarin (SLM) on the expression TNF-a, IL-6, CRP and symptoms of PCOS were studied. In this research, PCOS was induced by injection of Estradiol Valerate. PCOS rats were divided into control and experimental groups received intraperitoneal injection SLM extract daily. After syndrome induction, ovaries were collected for histological and immunohistochemical evaluations. Serum IL-6 was detected by the ELISA kit. The results indicated the significant reduction in inflammatory markers and significant changes follicular layers thickness in the treatment group as compared with control. It can be concluded that having anti-inflammatory substances, Silymarin is effective in symptoms of this syndrome and metabolic syndrome.

El factor de necrosis tumoral alfa (TNF-a) y la interleucina (IL) -6 son mediadores prominentes de la inflamación y se ha confirmado que están elevados en al menos un subgrupo de mujeres con síndrome de ovario poliquístico (SOP). En este estudio se estudiaron los efectos de Silymarin (SLM) en la expresión TNF-a, IL-6, PCR y síntomas de SOP. El SOP fue inducido por inyección de valerato de estradiol. Las ratas SOP se dividieron en grupos control y los grupos experimentales recibieron diariamente un extracto de SLM por inyección intraperitoneal. Después de la inducción del síndrome, los ovarios se analizaron mediante histología e inmunohistoquímica. Se detectó IL-6 en suero mediante el kit ELISA. Los resultados indicaron una reducción significativa en los marcadores inflamatorios y cambios significativos en el espesor de las capas foliculares en el grupo de tratamiento en comparación con el control. Se puede concluir que con sustancias anti-inflamatorias, Silymarin es eficaz en los síntomas de este síndrome y el síndrome metabólico.
Descritores: Anti-Inflamatórios/farmacologia
Síndrome do Ovário Policístico/metabolismo
Silimarina/farmacologia
Fator de Necrose Tumoral alfa/metabolismo
-Imuno-Histoquímica
Inflamação
Interleucina-6/metabolismo
Ratos Wistar
Fator de Necrose Tumoral alfa/efeitos dos fármacos
Limites: Animais
Feminino
Ratos
Responsável: CL1.1 - Biblioteca Central


  10 / 22 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-670907
Autor: Brazilian Journal of Medical and Biological Research; Yao, Jiayin; Zhi, Min; Gao, Xiang; Hu, Pinjin; Li, Chujun; Yang, Xiaobo.
Título: Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;46(3):270-277, 15/mar. 2013. tab, graf.
Idioma: en.
Projeto: National Natural Science Foundation of China; . Federal Office of Public Health of Guangdong Province of China.
Resumo: Our previous study has shown that reduced insulin resistance (IR) was one of the possible mechanisms for the therapeutic effect of silibinin on non-alcoholic fatty liver disease (NAFLD) in rats. In the present study, we investigated the pathways of silibinin in regulating hepatic glucose production and IR amelioration. Forty-five 4- to 6-week-old male Sprague Dawley rats were divided into a control group, an HFD group (high-fat diet for 6 weeks) and an HFD + silibinin group (high-fat diet + 0.5 mg kg-1·day-1 silibinin, starting at the beginning of the protocol). Both subcutaneous and visceral fat was measured. Homeostasis model assessment-IR index (HOMA-IR), intraperitoneal glucose tolerance test and insulin tolerance test (ITT) were performed. The expression of adipose triglyceride lipase (ATGL) and of genes associated with hepatic gluconeogenesis was evaluated. Silibinin intervention significantly protected liver function, down-regulated serum fat, and improved IR, as shown by decreased HOMA-IR and increased ITT slope. Silibinin markedly prevented visceral obesity by reducing visceral fat, enhanced lipolysis by up-regulating ATGL expression and inhibited gluconeogenesis by down-regulating associated genes such as Forkhead box O1, phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Silibinin was effective in ameliorating IR in NAFLD rats. Reduction of visceral obesity, enhancement of lipolysis and inhibition of gluconeogenesis might be the underlying mechanisms.
Descritores: Antioxidantes/farmacologia
Resistência à Insulina/fisiologia
Fígado/efeitos dos fármacos
Hepatopatia Gordurosa não Alcoólica/tratamento farmacológico
Silimarina/farmacologia
-Teste de Tolerância a Glucose
Homeostase
Metabolismo dos Lipídeos/efeitos dos fármacos
Fígado/metabolismo
Fígado/patologia
Hepatopatia Gordurosa não Alcoólica/patologia
Hepatopatia Gordurosa não Alcoólica/fisiopatologia
Ratos Sprague-Dawley
Fatores de Tempo
Limites: Animais
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde